Author: Rodrigo Arrangoiz MS, MD, FACS, FSSO

• ESMO 2026 Breast Cancer: 10 Studies to Watch in Madrid
  ESMO Congress 2026 takes place in Madrid, Spain, from 23 to 27 October 2026. OncoDaily picked ten breast cancer abstracts from the official programme. The programme covers both early and advanced disease, with late-breaking phase III trials, mature overall survival (OS) analyses, post-CDK4/6 strategies, biomarker studies and a growing focus on how to sequence antibody–drug conjugates (ADCs). [1]
  Early breast cancer
  1. TALENT (LBA23): T-DXd before surgery in HER2-low, HR+ disease
  This presentation reports final results of a neoadjuvant study testing trastuzumab deruxtecan (T-DXd) with or without anastrozole, or in sequence with chemotherapy, in HER2-low, HR-positive early breast cancer. Earlier data from the phase II trial were presented at SABCS 2022, where investigators stressed that pCR and response results were not yet mature because not all patients had completed scans or surgery. [2, 3]
  2. NATALEE (LBA25): Six-year follow-up of adjuvant ribociclib
  ESMO 2026 will show six-year OS and efficacy outcomes for adjuvant ribociclib plus a nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer. At the 5-year analysis, invasive disease-free survival was 85.5% with ribociclib plus endocrine therapy versus 81.0% with endocrine therapy alone, a 4.5% absolute improvement. The hazard ratio was 0.716 (95% CI 0.618–0.829). OS data were still immature at that point. [4, 5]
  Advanced HR+/HER2− breast cancer
  3. PANKU-Breast01 (LBA50): iza-bren after prior treatment
  This randomized phase III study tests izalontamab brengitecan in previously treated, unresectable locally advanced or metastatic HR+/HER2− breast cancer. The same drug, an EGFR×HER3 bispecific ADC, already succeeded in triple-negative disease. In the PANKU-Breast02 trial in pretreated TNBC, presented at ASCO 2026, the hazard ratio for PFS was 0.29. Risk of death was 40% lower (HR 0.60; 95% CI 0.42–0.85). [6]
  4. KEYNOTE-B49 (LBA51): Pembrolizumab plus chemotherapy
  This double-blind phase III study compares pembrolizumab with placebo, both added to chemotherapy, in HR+/HER2− advanced breast cancer. It enrolled about 800 patients with PD-L1 CPS ≥1 tumours who had progressed on endocrine therapy and had not received chemotherapy for metastatic disease. These will be the first reported results. [7, 8]
  5. FINER / MA.40 (LBA14): OS with ipatasertib plus fulvestrant
  This presentation reports OS from the randomized phase III trial of fulvestrant plus ipatasertib in ER+/HER2− metastatic breast cancer. The trial randomized 250 patients whose disease had progressed after first-line CDK4/6 inhibitor plus aromatase inhibitor. At ASCO 2025, median PFS was 5.32 months with ipatasertib versus 1.94 months with placebo. In patients with AKT-pathway alterations, median PFS was 5.45 vs 1.91 months (HR 0.47). [9, 10]
  6. VIKTORIA-1 (LBA16): Updated gedatolisib results
  This presentation gives updated results for gedatolisib plus fulvestrant, with or without palbociclib, versus standard of care in HR+/HER2− advanced breast cancer. In the PIK3CA wild-type cohort, median PFS was 9.3 months with the triplet versus 2.0 months with fulvestrant (HR 0.24), and 7.4 months with the doublet (HR 0.33). These results were published in the Journal of Clinical Oncology in March 2026. The FDA has since approved gedatolisib for HR+/HER2−, PIK3CA wild-type advanced breast cancer. [11, 12]
  7. evERA (2RO): Biomarker analyses for giredestrant plus everolimus
  The focus here is retrospective exploratory biomarker analyses, not another efficacy readout. In the primary analysis, median PFS was 8.77 months with giredestrant plus everolimus versus 5.49 months with endocrine therapy plus everolimus (HR 0.56; 95% CI 0.44–0.71). The benefit was larger in ESR1-mutated tumours, with a 62% reduction in risk of progression or death. [13, 14]
  8. postMONARCH (1RO): OS with abemaciclib after a prior CDK4/6 inhibitor
  This presentation reports OS for abemaciclib plus fulvestrant versus placebo plus fulvestrant after progression on a CDK4/6 inhibitor plus endocrine therapy. The primary analysis of 368 patients showed a PFS hazard ratio of 0.73, with median PFS of 6.0 vs 5.3 months. Blinded central review supported this result (HR 0.55). [15, 16]
  Triple-negative disease and ADC sequencing
  9. OptiTROP-Breast01 (4639RO): Final OS for sac-TMT
  This is the final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated metastatic TNBC. In the published phase III data, median PFS by central review was 6.7 vs 2.5 months (HR 0.32). At the interim OS analysis, median OS was not reached with sac-TMT versus 9.4 months with chemotherapy (HR 0.53). [17, 18]
  10. SWITCH (4RO): What to do after a first ADC stops working
  This is a prospective phase II platform trial in metastatic breast cancer after prior ADC therapy. It tests switching to a novel ADC with a different target but the same type of payload. No earlier results have been published. [1]
  The bottom line
  Four of these studies bring long-awaited survival data: NATALEE, FINER, postMONARCH and OptiTROP-Breast01. The rest address newer questions, including ADCs in early HER2-low disease, immunotherapy in HR+ disease, treatment after CDK4/6 inhibitors, and what to give after an ADC. The common theme is choosing the right sequence of treatments, not just finding one new active drug.
  References
  Gevorgyan A. ESMO Congress 2026 Breast Cancer: 10 Abstracts to Watch. OncoDaily, 28 Sep 2026. https://oncodaily.com/breast-oncology/esmo-congress-2026-bc
  Hurvitz S, et al. Final results of TALENT. ESMO 2026, LBA23.
  Hurvitz SA, Bardia A, et al. TRIO-US B-12 TALENT. SABCS 2022, GS2-03. https://ascopost.com/news/december-2022/neoadjuvant-t-dxd-shows-clinical-activity-in-patients-with-her2-low-breast-cancer/
  Slamon D, et al. NATALEE 6-year OS. ESMO 2026, LBA25.
  NATALEE 5-year follow-up (PMC); Novartis press release, 17 Oct 2025. https://pmc.ncbi.nlm.nih.gov/articles/12684762 · https://www.novartis.com/news/media-releases/novartis-kisqali-5-year-natalee-data-demonstrate-28-reduction-risk-recurrence-broadest-early-breast-cancer-patient-population
  Lan B, et al. PANKU-Breast01. ESMO 2026, LBA50. PANKU-Breast02 background: https://www.cancernetwork.com/view/izalontamab-brengitecan-improves-os-pfs-in-advanced-metastatic-tnbc
  Rugo H, et al. KEYNOTE-B49. ESMO 2026, LBA51.
  KEYNOTE-B49 trial design (ASCO TPS); ClinicalTrials.gov NCT04895358. https://ace.asco.org/content/370330/abstract/213426
  Redfern A, et al. FINER OS. ESMO 2026, LBA14.
  Chia S, et al. FINER, ASCO 2025. https://www.hmpgloballearningnetwork.com/site/onc/conference-coverage/ipatasertib-plus-fulvestrant-significantly-prolongs-progression-free
  Pistilli B, et al. VIKTORIA-1 update. ESMO 2026, LBA16.
  VIKTORIA-1, J Clin Oncol, Mar 2026; FDA approval coverage. https://www.targetedonc.com/view/fda-approves-gedatolisib-for-hr-her2-pik3ca-wild-type-advanced-breast-cancer
  Tolaney S, et al. evERA biomarker analyses. ESMO 2026, 2RO.
  evERA primary results, ESMO 2025. https://www.cancernetwork.com/view/giredestrant-combo-yields-positive-pfs-in-subgroups-after-cdk4-6i-in-er-her2-breast-cancer
  Kalinsky K, et al. postMONARCH OS. ESMO 2026, 1RO.
  Kalinsky K, et al. J Clin Oncol 2024 (postMONARCH primary). https://unifind.unisr.it/resource/item/236996
  Fan Y, et al. OptiTROP-Breast01 final OS. ESMO 2026, 4639RO.
  OptiTROP-Breast01 phase III publication (2025). https://cancer.fr/professionnels-de-sante/veille/nota-bene-cancer/bulletin-n-640/sacituzumab-tirumotecan-in-previously-treated-metastatic-triple-negative-breast-cancer-a-randomized-phase-3-trial
  Liu X, et al. SWITCH. ESMO 2026, 4RO.

• NCCN Guidelines, Head and Neck Cancers (v2.2026) still base clinical staging definitions on AJCC 8th edition (ST-4 for p16-negative, ST-7 for p16-positive):
  • Version 9 is not yet incorporated
• Version 9 changes apply only to:
  • HPV-positive (p16+) oropharyngeal carcinoma
• The p16-negative oropharynx / hypopharynx system:
  • Is unchanged in the current NCCN tables
• T – Tumor:
  • TX – Primary tumor cannot be assessed
  • Tis – Carcinoma in situ
  • T1 – Tumor 2 cm or smaller in greatest dimension
  • T2 – Tumor larger than 2 cm but not larger than 4 cm in greatest dimension
  • T3 – Tumor larger than 4 cm in greatest dimensión or extensión to lingual surface of epiglottis
  • T4 – Moderately advanced or very advanced local disease
    • T4a – Moderately advanced local disease
      • Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid muscle, hard palate, or mandible
    • T4b – Very advanced local disease
      • Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery

• The rate of cancer development in setting of LCIS:
  • Has been reported to be approximately 1% to 2% per year:
    • Translating into a cumulative long-term rate of 26% at 15 years
• While a minority of patients elect to proceed with bilateral prophylactic mastectomy for LCIS:
  • The estimated breast cancer incidence is generally not considered high enough to justify such extensive surgery
  • Furthermore, women with a history of LCIS:
    • Typically develop low- or intermediate-grade malignancies clinically detected at an early stage
• Multiple studies support a low upgrade rate on excision (1% to 5% for patients diagnosed with LCIS on core biopsy and rad-path concordant) with a 1% upgrade rate reported in a prospective study with central pathology review:
  • Therefore surgical excision is not routinely indicated
• The risk conferred by LCIS:
  • Is independent of family history
• Chemoprevention:
  • Reduces breast cancer risk by 40% to 65% in women at elevated risk:
    • Data from the NSABP P-1 trial suggest that women with LCIS derive even greater benefit than this estimate
• References:
  • King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33(33):3945–3952.
  • Wong SM, King T, Boileau JF, Barry WT, Golshan M. Population-based analysis of breast cancer incidence and survival outcomes in women diagnosed with lobular carcinoma in situ. Ann Surg Oncol. 2017;24(9):2509-2517.
  • Nakhlis F, Gilmore L, Gelman R, et al. Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). Ann Surg Oncol. 2016;23(3):722-728.
  • King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251-2256.

• A painless neck mass (metastatic cervical lymphadenopathy) and sore throat:
  • Are the two most common presenting features of oropharyngeal squamous cell carcinoma (OPSCC):
    • But the pattern differs strongly by HPV status:
      • HPV-associated tumors (tonsil, base of tongue) frequently present with an asymptomatic or occult primary and a cervical neck mass
      • HPV-negative tumors more often produce local symptoms from the primary site such as sore throat, dysphagia, and odynophagia:
        • Because these symptoms overlap with benign conditions (reflux, globus, branchial cleft cyst), any persistent neck mass or throat symptom in an adult should be considered malignant until proven otherwise
• Most common presenting symptoms / signs:
  • Neck mass (cervical lymphadenopathy):
    • The single most frequent initial complaint (~ 44% to 52%):
      • Typically a new, painless, often cystic level II node:
        • Commonly the first and only sign of an HPV-associated primary
  • Sore throat:
    • Persistent, often unilateral (~ 33%)
  • Dysphagia:
    • Difficulty swallowing
  • Odynophagia:
    • Pain on swallowing
  • Otalgia:
    • Referred ear pain via the glossopharyngeal /vagal pathways:
      • Especially with tonsil and base-of-tongue lesions
  • Globus sensation:
    • Feeling of a mass or fullness in the throat
  • Visualized oropharyngeal mass or tonsillar asymmetry / ulceration
• Less common / advanced-disease features:
  • Voice change / muffled (“hot potato”) voice
  • Hemoptysis or blood-tinged saliva
  • Unintentional weight loss
  • Trismus and impaired tongue mobility / dysarthria:
    • Reflecting deep muscular or hypoglossal nerve involvement (base of tongue), often signaling locally advanced disease
  • Otalgia with a normal otologic exam:
    • Should specifically prompt oropharyngeal evaluation
  • HPV-positive vs HPV-negative presentation:
    • This distinction is clinically important because it drives suspicion in patients lacking traditional tobacco / alcohol risk factors

• Clinical caveats:
  • HPV-associated cystic nodal metastases are frequently mistaken for benign cysts:
    • The prevalence of malignancy in a cystic neck mass in patients > 40 years is approximately 80%:
      • So FNA (ideally image-guided) is warranted rather than observation
  • Anatomically hidden oropharyngeal primaries become symptomatic late, so absence of a visible lesion does not exclude malignancy:
    • Nasolaryngoscopy and cross-sectional imaging are indicated for persistent symptoms
  • OPSCC is a leading cause of carcinoma of unknown primary:
    • p16 / HPV testing of nodal tissue helps localize the oropharynx as the source
• References:
  • Dunn LA, Ho AL, Pfister DG. Head and Neck Cancer. JAMA. 2025.
  • McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial Symptoms in Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2014.
  • Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020.
  • Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022.
  • Wilbur J, Tran VL, Doobay MF. Evaluation of Neck Masses in Adults. Am Fam Physician. 2026.
    Dunn LA, Ho AL, Pfister DG. Head and Neck Cancer. JAMA. 2025.
  • Khalid MB, Ting P, Pai A, et al. Initial Presentation of Human Papillomavirus-Related Head and Neck Cancer: A Retrospective Review. Laryngoscope. 2019.
  • McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial Symptoms in Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2014.
  • Lawless AK, Duruchukwu E, Bergamin S, et al. De-Escalation of Radiotherapy in the Treatment of Human Papillomavirus-Associated Oropharyngeal Cancer. Cochrane Database Syst Rev. 2025.
  • McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial Symptoms in Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2014.
  • Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020.
  • Jerjes W, Upile T, Hamdoon Z, et al. Photodynamic therapy: The minimally invasive surgical intervention for advanced and/or recurrent tongue base carcinoma. Lasers Surg Med. 2011.
  • Wilbur J, Tran VL, Doobay MF. Evaluation of Neck Masses in Adults. Am Fam Physician. 2026.
  • Amin JD, Rodriggs T, Weir KA, Snider JW, Hatten KM. Prospective Evaluation of Swallowing Symptoms in Human Papillomavirus-Associated Oropharynx Cancer. Dysphagia. 2022.
  • Dunn LA, Ho AL, Pfister DG. Head and Neck Cancer. JAMA. 2025.

• Lobular neoplasia (LN):
  • Is an umbrella term for a spectrum of non-invasive, dyscohesive epithelial proliferations arising in the terminal duct-lobular unit (TDLU)
  • It encompasses:
    • Atypical lobular hyperplasia (ALH)
    • Lobular carcinoma in situ (LCIS)
      • Subdivided into:
        • Classic (C-LCIS)
        • Florid (F-LCIS)
        • Pleomorphic (P-LCIS)
      • Nakhlis et al., JAMA Surgery, 2026; Tjendra and Susnik, Seminars in Diagnostic Pathology, 2025
  • Its defining molecular feature is:
    • Loss of E-cadherin membrane expression:
      • A CDH1-encoded cell-adhesion protein
  • LN is both a:
    • Risk marker for—and a non-obligate precursor of—invasive breast cancer in either breast:
      • With most subsequent cancers being invasive ductal rather than lobular (Morrow et al., Nature Reviews Clinical Oncology, 2015)
• Definition and Histopathologic Classification:
  • The WHO classifies non-invasive LN by:
    • Nuclear atypia and architecture into:
      • ALH and LCIS (classic, florid, pleomorphic)
  • The common cytology is:
    • A non-cohesive, non-polarized proliferation of small monotonous cells with scant cytoplasm and low-grade nuclei:
      • Frequently with intracytoplasmic vacuoles producing a “fried egg” or signet-ring appearance:
        • Pagetoid extension up adjacent ducts is common (Brogi, Virchows Archiv, 2022; Kuba and Brogi, Histopathology, 2023)
  • ALH vs. C-LCIS (quantitative distinction):
    • The threshold is the proportion of acini that are both filled and distended (> 8 to 10 cells across):
      • LCIS:
        • Is diagnosed when > 50% of acini within a TDLU are filled and distended
      • ALH:
        • Is diagnosed when ≤ 50% are involved with only minimal expansion
    • The cells are cytologically indistinguishable:
      • ALH and C-LCIS are often grouped as classic LN and represent a morphologic continuum (Nakhlis et al., JAMA Surgery, 2026; Jani et al., The Breast Journal, 2022)
    • Florid LCIS (F-LCIS):
      • Cells resemble C-LCIS but there is marked acinar distention (~ 40 to 50 cells across) with little to no intervening stroma (often mass-forming) and frequent comedo-type necrosis / calcification (Brogi, Virchows Archiv, 2022)
    • Pleomorphic LCIS (P-LCIS):
      • High-grade pleomorphic nuclei > 4× the size of a lymphocyte (similar to high-grade DCIS):
        • Sometimes with apocrine features and necrosis (Kuba and Brogi, Histopathology, 2023)
  • Immunophenotype:
    • Classic LN is:
      • Typically ER / PR-positive and HER2-negative
    • F-LCIS and P-LCIS:
      • Can show less favorable phenotypes
      • P-LCIS:
        • In particular may be ER-negative and carries recurrent ERBB2 alterations
  • E-cadherin loss:
    • Distinguishes LN from DCIS (Jani et al., The Breast Journal, 2022; Chung et al., Breast Cancer Research and Treatment, 2024)
• Incidence:
  • True population incidence is unknown:
    • Because classic LN is clinically and mammographically occult
  • Historically it is reported in 1% to 4% of benign breast biopsies
• Incidence of C-LCIS:
  • Has risen an estimated two- to fourfold since the 1980s:
    • Attributed to increased biopsy volume, improved imaging and immuno-histochemistry, and population aging
  • C-LCIS is most common in premenopausal women (median age 51 to 55)
  • Historically C-LCIS:
    • Is multicentric in ~ 80% of the cases
    • Bilateral in ~ 40% of the cases (Brogi, Virchows Archiv, 2022)
• Incidence of P-LCIS is rare:
  • A SEER analysis (ICD-O-3 code 8519/2) found an age-adjusted incidence of 0.08 per 100,000 woman-years versus 4.68 for classic disease:
    • Comprising 2.6% of LCIS and peaking at ages 65 to 69 (Zihni and Sabuncuoğlu, Clinical Breast Cancer, 2026)
• Breast Cancer Risk:
  • LN confers a bilateral, lifelong elevation in breast cancer risk (Harris et al., New England Journal of Medicine, 1992; Morrow et al., Nature Reviews Clinical Oncology, 2015)
    • See table 1
  • The annual risk for LCIS is a steady ~1% to 2% per year:
    • Translating to a lifetime risk often cited as 30% to 40% and inversely related to age at diagnosis:
      • Example: ~40% at age 50 vs. ~30% at age 60)
    • In a cohort of 1,060 women with C-LCIS:
      • The cumulative cancer rate was 7% at 5 years and 21% at 10 years without chemoprevention
    • Risk is distributed to both breasts:
      • Though contemporary data suggest an ipsilateral predilection:
        • One series found 90.9% of subsequent cancers ipsilateral (63.6% at the LCIS site), supporting a precursor role
    • Most subsequent cancers are:
      • Ductal, early- stage, ER-positive, HER2-negative, and low / intermediate grade:
        • With breast cancer–specific survival exceeding 95% at 10 years
    • Importantly, standard risk models (Gail, Tyrer-Cuzick) do not accurately estimate risk in patients with ALH / LCIS (Nakhlis et al., JAMA Surgery, 2026; Chung et al., Breast Cancer Research and Treatment, 2024)
• Diagnostic Imaging Findings:
  • Classic LN (ALH, C-LCIS) is usually mammographically and clinically occult and discovered incidentally when biopsying another target:
    • Mammography misses > 30% of lobular lesions owing to the subtle, infiltrative growth pattern
  • When findings are present:
    • Mammography:
      • Grouped amorphous calcifications are the most common finding:
        • Often associated with adjacent columnar cell change rather than the LN itself
      • P-LCIS and F-LCIS are more often the actual imaging target, typically as:
        • Pleomorphic / suspicious calcifications
    • Ultrasound:
      • Low, operator-dependent sensitivity; when a correlate exists it is usually:
        • An irregular, hypoechoic, avascular, shadowing mass
    • MRI:
      • Most sensitive (> 90%), best for defining extent and detecting multifocality / multicentricity; typical appearance is heterogeneous non-mass enhancement with persistent kinetics
    • Contrast-enhanced mammography (CEM):
      • Preliminary data show performance comparable to MRI for detection, extent, and multifocality, predominantly as non-mass enhancement
        (Scoggins et al., Academic Radiology, 2013; Nicosia et al., Breast Cancer Research and Treatment, 2024; Amitai et al., Breast Cancer Research and Treatment, 2020)
• Management:
  • Management hinges on the specific lesion and on radiologic-pathologic concordance (Nakhlis et al., JAMA Surgery, 2026; NCCN Breast Cancer Screening and Diagnosis, 2026)
  • ALH and classic LCIS on core needle biopsy:
    • Routine surgical excision is not required in the presence of radiographic-pathologic concordance:
      • Because of exceedingly low upgrade rates:
        • Select patients may be suitable for monitoring in lieu of excision
    • Excision should be considered case-by-case when there is:
      • Radiologic-pathologic discordance
      • Concerning histologic features:
        • Marked atypia or necrosis
      • Inadequate sampling
  • Surveillance typically includes:
    • Clinical examination and / or imaging at 6 to 12 months before returning to routine screening, with supplemental MRI considered on the basis of overall risk
  • Counseling on risk reduction should be offered, including endocrine chemoprevention (e.g., tamoxifen in premenopausal, and tamoxifen or an aromatase inhibitor / raloxifene in postmenopausal women
  • Pleomorphic LCIS and florid LCIS on core needle biopsy:
    • Complete surgical excision with negative margins is recommended:
      • Given upgrade rates approaching 40%
    • Outcomes data for these non-classic variants remain limited
  • Bilateral risk-reducing mastectomy:
    • Is reserved for a minority of patients with additional risk factors (e.g., strong family history, deleterious germline mutation) and requires individualized multidisciplinary discussion
      (Nakhlis et al., JAMA Surgery, 2026; NCCN Breast Cancer Screening and Diagnosis, 2026; Jani et al., The Breast Journal, 2022; Elfgen et al., Virchows Archiv, 2023)

• The National Comprehensive Cancer Network (NCCN) recommends:
  • That every patient with suspected oropharyngeal squamous cell carcinoma (OPSCC) undergo a structured workup anchored by:
    • Mandatory tumor HPV testing by p16 immunohistochemistry (IHC), tissue confirmation, cross-sectional imaging, and clinical staging by AJCC 8th edition:
      • With p16 status determining which staging table and treatment algorithm applies
• Required workup elements (base of tongue / tonsil / posterior pharyngeal wall / soft palate):
  • Tumor HPV testing by p16 IHC is required:
    • The 70% cutoff with nuclear and cytoplasmic expression of at least moderate-to-strong intensity is used:
      • Direct HPV confirmatory testing (PCR or RNA ISH) is recommended, especially for clinical trials and when p16 is used as a surrogate
  • History and physical including a complete head and neck exam, with mirror and fiberoptic examination as clinically indicated:
    • H&P should document / quantify tobacco (pack-years) and alcohol use with counseling, and screen for distress
  • Biopsy of the primary site or FNA of the neck:
    • Image-guided (US or CT) needle biopsy of cystic neck nodes offers better yield than palpation-guided FNA:
      • A core biopsy is preferred when biomarker testing is planned for unresectable / metastatic disease
  • CT with contrast and / or MRI with and without contrast of the primary and neck
  • Additional studies as clinically indicated
    EUA with endoscopy:
    • Prior to treatment, EUA with biopsy confirmation of the oropharyngeal primary is recommended for patients presenting with a p16+ cervical node
  • FDG-PET/CT; chest CT (with or without contrast)
  • Dental evaluation:
    • Including Panorex
  • Nutrition, speech, and swallowing evaluation / therapy, and audiogram
  • Smoking cessation counseling
  • Fertility / reproductive counseling
  • Hepatitis B screening
  • PD-L1 testing by IHC (CPS)
  • Multidisciplinary consultation.
• Imaging principles:
  • Assess the primary with CT (with contrast) or MRI (with and without contrast) of the neck:
    • Imaging from skull base to thoracic inlet:
    • CT is complementary for cortical bone erosion
    • MRI is preferred for bone marrow invasion, skull base / intracranial / orbital invasion, and perineural spread, and in patients with extensive dental amalgam
    • Evaluate nodal disease with the same modality
    • Consider FDG-PET / CT for its higher sensitivity:
      • Particularly for midline tumors approaching the contralateral neck or when definitive RT is planned
      • For locoregionally advanced disease (T3 to T4 or ≥ N1), FDG-PET/CT is preferred to evaluate for distant / thoracic metastases:
        • If PET / CT is not done, obtain chest CT
      • FDG-PET/CT cannot exclude brain metastasis
      • If imaging does not reveal an obvious primary:
        • PET / CT should be obtained before EUA, biopsies, and tonsillectomy to identify potential primary sites before intervention
• Search for the occult primary (neck mass presentation):
  • Because the first sign of OPSCC is often a neck mass with a small, asymptomatic, radiographically occult primary:
    • The NCCN emphasizes diligent identification and pathologic confirmation of the primary:
      • Usually in the base of tongue or tonsil
  • Cross-sectional imaging:
    • Should precede direct examination and confirmatory biopsy
  • EUA may entail unilateral or bilateral biopsies of suspicious oropharyngeal areas:
    • Palatine tonsillectomy may reveal a small primary, and lingual tonsillectomy may be considered if palatine tonsils and biopsies are negative:
      • Bilateral palatine and lingual tonsillectomies are ill-advised due to swallowing morbidity
  • FNA of the neck mass (often US-guided) usually establishes metastatic carcinoma:
    • p16 immunostaining supports HPV-associated OPSCC when an oropharyngeal primary is present
  • In occult-primary cases with p16-positive nodal metastasis, confirmation with HPV ISH / PCR is recommended:
    • Open excisional node biopsy is rarely needed:
      • If performed, the surgeon should be prepared for neck dissection if frozen section confirms SCC
  • The occult-primary pathway similarly directs HPV / EBV testing on nodal SCC:
    • If HPV-positive with a T0 primary, the patient is treated as oropharyngeal cancer (ORPH-1)
• Clinical staging (AJCC 8th edition):
  • p16 status splits OPSCC into two separate staging systems:
    • p16-negative OPSCC is staged with the oropharynx (p16-) / hypopharynx TNM (ST-6):
      • Which incorporates extranodal extension (ENE) into N categories
    • p16-positive (HPV-mediated) OPSCC uses a distinct TNM (ST-7):
      • With different clinical N categories:
        • N1: ipsilateral nodes ≤ 6 cm
        • N2: contralateral / bilateral ≤ 6 cm
        • N3: > 6 cm
      • A separate pathologic N classification:
        • pN1 ≤ 4 nodes
        • pN2 > 4 nodes
      • Stage groups that markedly downstage nodal disease relative to p16-negative cancer
      • There is no Tis or T4b category, and no histologic grading system, for HPV-mediated tumors
• The following NCCN algorithm summarizes the oropharynx workup and the p16-based staging / treatment branch point

• HPV / p16 testing nuances that affect prognosis and staging:
  • While p16 IHC is the preferred surrogate for AJCC 8th edition staging:
    • Roughly 9% to 20% of p16-positive OPSCC lack detectable HPV DNA / mRNA, and these p16+ / HPV− (and p16−/HPV+) discordant tumors:
      • Carry a worse prognosis than double-positive tumors
    • The 2025 College of American Pathologists update supports p16 IHC alone in high-prevalence regions (US, Canada, Northern Europe) when clinicopathologic surrogates of HPV disease are present:
      • But recommends adding HPV-specific testing (RNA-ISH or DNA PCR) when p16 is equivocal, when morphology and p16 are discordant, for large multisite tumors, for nontonsillar / non–base-of-tongue oropharyngeal sites, in low-prevalence regions, and for clinical trials
• Examination under anesthesia and tonsillectomy for the occult primary :
  • The AAO-HNS neck mass guideline advises that when a persistent neck mass evades diagnosis after FNA, imaging, and exam, endoscopy under anesthesia with directed biopsies should precede open neck biopsy to avoid tumor seeding and its associated complications:
    • A meta-analysis found palatine tonsillectomy has ~ 10-fold higher diagnostic yield than blind tonsil biopsy for detecting occult primaries:
      • Because tonsillar tumors often lie deep within crypts or submucosa
• Imaging modality performance:
  • For detecting nodal metastases, high-resolution CT has ~ 82% sensitivity / 85% specificity, whereas PET/CT reaches ~ 90% sensitivity / 94% specificity
  • Dedicated brain imaging is reserved for neurologic symptoms
  • The ACR Appropriateness Criteria list CT neck with contrast, MRI without / with contrast, and FDG-PET / CT as the recommended studies for initial staging of oral cavity / oropharyngeal cancer, with FDG-PET / CT complementary for mapping systemic disease and detecting synchronous second primaries
• Special populations:
  • A diagnosis of HNSCC in an adolescent or young adult without risk factors warrants evaluation for Fanconi anemia

• Overview:
  • Treatment is driven first by p16 / HPV status:
    • Which assigns separate AJCC 8th edition staging, and then by T / N category:
      • With the overarching NCCN principle of:
        • Using the fewest modalities necessary to control disease while preserving speech and swallowing and avoiding triple-modality therapy (surgery + RT + chemotherapy) whenever possible (NCCN, Head and Neck Cancers, 2026; Dunn et al., JAMA, 2026)
  • For a resectable primary:
    • Upfront surgery (increasingly TORS) and definitive radiation ☢️ or chemoradiation are both curative-intent options with comparable survival in HPV-positive disease:
      • The choice is a shared decision balancing functional outcomes (Nichols et al., Journal of Clinical Oncology, 2024; Hoenle et al., European Archives of Oto-Rhino-Laryngology, 2026)
  • Two absolute surgical caveats from NCCN:
    • Patients with fixed or matted nodes or obvious extranodal extension (ENE):
      • Are not candidates for upfront definitive surgery:
        • Concurrent chemoradiation is preferred
    • T4b or unresectable disease:
      • Goes to definitive systemic therapy / RT (NCCN, Head and Neck Cancers, 2026).
• p16 Testing and Staging (First Branch Point):
  • NCCN requires p16 IHC on every oropharyngeal tumor:
    • With positivity defined as ≥70% nuclear and cytoplasmic staining of moderate-to-strong intensity
  • Confirmatory direct HPV testing (PCR or RNA-ISH) is recommended:
    • Particularly because p16+ / HPV– discordant tumors:
      • Behave more like p16-negative disease
  • p16-positive tumors:
    • Are staged separately and assigned substantially lower stages:
      • Reflecting their better prognosis and radiosensitivity (NCCN, Head and Neck Cancers, 2026; Mehanna et al., Lancet Oncology, 2023)
• Surgery: Open vs TORS
  • Oncologic principles are identical to open resection:
    • But transoral approaches (TORS / TLM) avoid transmandibular / transcervical incisions and yield markedly better functional outcomes:
      • Lower tracheostomy and feeding-tube rates, less free-flap reconstruction, shorter stay, and faster return of swallowing :
        • Without a difference in margins or survival in comparative series (Park et al., European Journal of Surgical Oncology, 2020; Roselló et al., Medicina Oral Patología Oral y Cirugía Bucal, 2020; Cramer et al., Nature Reviews Clinical Oncology, 2019)
  • The randomized ORATOR trial (T1 to T2, N0 to N2):
    • Found no difference in overall or progression-free survival between primary RT and TORS at 5 years
    • Toxicity profiles differed:
      • More xerostomia with RT
      • More pain / dysphagia with TORS:
        • So modality choice remains a shared decision (Nichols et al., Journal of Clinical Oncology, 2024)
  • The 2025 ASCO TORS guideline frames candidacy (Holsinger et al., Journal of Clinical Oncology, 2025):
    • TORS should be discussed for T1 to T2 tumors:
      • When preoperative multimodal assessment predicts a high probability of R0 resection
    • Select exophytic T3 tumors:
      • Where resection will not cause significant functional deficit may be considered (off-label), case-by-case within a multidisciplinary team
    • T4 tumors should not be offered transoral surgery alone
    • Contraindications / limitations to adequate exposure:
      • Trismus from pterygoid muscle invasion, narrow mandibular arch or tori, and tumors where pharyngeal vessels cannot be controlled (bleeding risk)
      • Exposure should be confirmed in-office and again under anesthesia.
  • Open surgery remains appropriate:
    • When exposure, tumor size / location, defect management, or reconstruction needs make transoral resection inadequate:
      • The approach should be dictated by these factors and surgeon experience, not by a blanket preference
• A key rationale for upfront TORS in HPV-positive disease is:
  • Pathology-guided de-escalation of adjuvant therapy:
    • In ECOG 3311:
      • ~ 70% of patients were safely spared standard-intensity adjuvant therapy, and 5-year OS was 95% (Holsinger et al., Journal of Clinical Oncology, 2025; Mody et al., Lancet, 2021)
• Neck Dissection: When and How Much:
  • Any patient treated with upfront surgery for the primary:
    • Should undergo concurrent neck dissection (Koyfman et al., Journal of Clinical Oncology, 2019)
  • Lateralized tumors:
    • Ipsilateral selective neck dissection of levels II to IV, with an adequate yield of ≥ 18 lymph nodes (a quality metric associated with better survival and locoregional control) (NCCN, Head and Neck Cancers, 2026; Koyfman et al., Journal of Clinical Oncology, 2019)
  • Bilateral neck dissection:
    • For tumors of the base of tongue, soft palate, posterior pharyngeal wall, or lesions at /approaching midline (and tonsil tumors invading the tongue base) — unless bilateral adjuvant RT is already planned
    • If TORS is chosen for a near-midline tongue base tumor, contralateral nodal management must be addressed, sometimes staged (Holsinger et al., Journal of Clinical Oncology, 2025; NCCN, Head and Neck Cancers, 2026)
  • Extent by nodal stage:
    • N0 → selective (oropharynx ≥ levels II to IV)
    • N1 to N2a–c → selective or comprehensive
    • N3 → comprehensive (NCCN, Head and Neck Cancers, 2026)
  • For pN0 to pN1 without adverse features:
    • Favor single-modality treatment:
      • Lateralized pN0 to pN1 with favorable pathology can be observed, and a staged contralateral neck dissection can be used to avoid RT in midline tumors resected to clean margins (NCCN, Head and Neck Cancers, 2026)
• Radiation Alone vs Definitive Chemoradiation
  • When nonsurgical treatment is chosen:
    • The distinction hinges on T and N category (indications derive from AJCC-7-era trial eligibility)
    • Definitive RT is 66 to 70 Gy
    • Concurrent chemoradiation uses 70 Gy with high-dose cisplatin 100 mg/m² every 3 weeks (category 1), with weekly cisplatin 40 mg/m² or carboplatin / 5-FU as alternatives (NCCN, Head and Neck Cancers, 2026; Dunn et al., JAMA, 2026)
  • RT alone:
    • Is appropriate for early, low-volume disease:
      • T1 to T2N0, and T1N1 (single node ≤ 3 cm)
    • A large Swedish registry analysis supports RT alone as safe for T1 to T2N1 to N2a disease (Margalit et al., Practical Radiation Oncology, 2024; Gooi et al., Head & Neck, 2016; Adrian et al., International Journal of Radiation Oncology Biology Physics, 2026)
    • T2N1 (single node ≤ 3 cm):
      • Either RT alone or concurrent chemoRT is acceptable (NCCN lists concurrent chemoRT as category 2B here) (Margalit et al., Practical Radiation Oncology, 2024; NCCN, Head and Neck Cancers, 2026)
    • Concurrent chemoradiation is recommended for all fit patients with T3 to T4 disease, ≥ 2 positive nodes, or a single node > 3 cm, based on OS / locoregional-control benefit across multiple trials (AJCC-7 stage III–IV ≈ AJCC-8 T1–2N1–3 and T3–4N0–3):
      • ASTRO emphasizes that when systemic therapy is warranted it must be concurrent, not induction / sequential, and cisplatin is standard — cetuximab is inferior for recurrence and survival (Margalit et al., Practical Radiation Oncology, 2024; Gooi et al., Head & Neck, 2016)
  • HPV status does not change the choice of systemic agent:
    • Ot is prognostic, not predictive, and no de-escalation regimen (cetuximab substitution or dose reduction to 60 Gy) has proven non-inferior to 70 Gy + cisplatin in phase III;
      • So de-escalation stays within trials (Holsinger et al., Journal of Clinical Oncology, 2025; Margalit et al., Practical Radiation Oncology, 2024; Petrelli et al., European Archives of Oto-Rhino-Laryngology, 2023)
  • Induction chemotherapy before RT / chemoRT remains category 3 in NCCN (NCCN, Head and Neck Cancers, 2026; Gooi et al., Head & Neck, 2016)
• Adjuvant Therapy After Surgery (Pathology-Directed):
  • Adverse features determine escalation:
    • ENE and / or positive margin:
      • Concurrent systemic therapy / RT (the high-risk indication established in RTOG 9501 / EORTC 22931, in largely HPV-unselected populations) (NCCN, Head and Neck Cancers, 2026)
    • Positive margin alone → re-resection if feasible, or RT, or chemoRT (NCCN, Head and Neck Cancers, 2026)
  • Other risk features (close margins < 3 mm, pT3 to pT4, multiple nodes or node > 3 cm, level IV / V nodes, PNI, LVI):
    • RT, or consider chemoRT (NCCN, Head and Neck Cancers, 2026)
  • Postoperative RT is:
    • 60 to 66 Gy for high-risk sites:
      • Ideally started ≤ 6 weeks after surgery (NCCN, Head and Neck Cancers, 2026)
  • In p16-positive disease the value of adding chemotherapy for ENE / positive margins is actively debated:
    • A propensity-matched analysis found no OS difference between adjuvant RT and chemoRT — and NCCN permits de-escalation to 50 Gy for selected intermediate-risk p16+ patients:
      • ECOG 3311 criteria:
        • ≤ 4 positive nodes ≤ 6 cm
        • T1 to T2 resected to negative / close margins with ≤ 1 mm ENE; category 2 (Fenlon et al., Head & Neck, 2022; NCCN, Head and Neck Cancers, 2026)
• Response Assessment and the Neck After Chemoradiation:
  • Response is evaluated with FDG-PET / CT:
    • Obtained ≥ 12 weeks after chemoradiation (Dunn et al., JAMA, 2026)
  • The PET-NECK randomized trial established PET / CT-guided surveillance rather than planned neck dissection for N2 to N3 disease:
    • It reduced operations with equivalent survival (Dunn et al., JAMA, 2026):
      • Patients with a complete metabolic response are observed
      • Those with residual / avid nodal disease proceed to salvage neck dissection
      • Equivocal findings may be followed with serial imaging (Koyfman et al., Journal of Clinical Oncology, 2019)
• Salvage Surgery:
  • For resectable locoregional recurrence, persistent disease, or a second primary after definitive (chemo)RT:
    • Salvage surgery is the cornerstone and often the only curative option:
      • Regardless of prior radiation (Fulcher et al., Head & Neck, 2018; Ward et al., Journal of the National Cancer Institute, 2026)
  • Patient selection is paramount:
    • Candidacy and outcome depend on recurrent T/N stage, site, disease-free interval, initial treatment, and locoregional vs limited local extent, weighed against significant functional morbidity (loss of larynx / pharynx function, tracheostomy / gastrostomy dependence) (Fulcher et al., Head & Neck, 2018; Patel et al., Head & Neck, 2016; Gañán et al., European Archives of Oto-Rhino-Laryngology, 2016)
    • HPV-positive recurrences salvage better:
      • In a secondary analysis of RTOG 1016, salvage surgery after locoregional failure improved 5-year OS versus no surgery (45% vs 17%) with acceptable late toxicity; salvage reduces death risk ~ 50%, with p16+ outperforming p16– (Lim et al., Oncogene, 2023; Quan et al., Cancer, 2023)
    • TORS is an increasingly used salvage option:
      • Within a previously irradiated field (weak evidence, strong ASCO recommendation) for appropriately selected, usually pT1 to pT2 recurrences, offering lower tracheostomy / gastrostomy dependence than open salvage:
        • The RECUT cohort showed 5-year local control ~ 62% and OS ~ 50%, with margins < 1 mm the strongest adverse factor
      • Larger recurrences require open resection, often with free-flap reconstruction that also introduces non-irradiated tissue to facilitate re-irradiation (Holsinger et al., Journal of Clinical Oncology, 2025; Ward et al., Journal of the National Cancer Institute, 2026; de Groot et al., Annals of Otology Rhinology & Laryngology, 2025)
    • After salvage:
      • Manage by pathologic risk features:
        • Re-irradiation (± chemotherapy) improves local control but adds substantial toxicity without a clear OS benefit, so it is individualized (Fulcher et al., Head & Neck, 2018; Leddon et al., Clinical Cancer Research, 2022).
• Works Cited:

Adrian, G., et al. “Chemoradiation Therapy Versus Radiation Therapy Alone in T1-2 Oropharyngeal Cancer With Low-Volume Neck Disease: A Population-Based Cohort Study Using the Swedish Head and Neck Cancer Register.” International Journal of Radiation Oncology Biology Physics, 2026.

Cramer, J. D., et al. “The Changing Therapeutic Landscape of Head and Neck Cancer.” Nature Reviews Clinical Oncology, 2019.

de Groot, E. C. M., et al. “Salvage Transoral Robotic Surgery With Submental Flap Reconstruction: Functional and Oncologic Outcomes.” Annals of Otology, Rhinology & Laryngology, 2025.

Dunn, L. A., A. L. Ho, and D. G. Pfister. “Head and Neck Cancer: A Review.” JAMA, 2026.

Fenlon, J. B., et al. “Comparing Adjuvant Radiation to Adjuvant Chemoradiation in Postsurgical p16+ Oropharyngeal Carcinoma Patients With Extranodal Extension or Positive Margins.” Head & Neck, 2022.

Fulcher, C. D., M. Haigentz, and T. J. Ow. “AHNS Series: Do You Know Your Guidelines? Principles of Treatment for Locally Advanced or Unresectable Head and Neck Squamous Cell Carcinoma.” Head & Neck, 2018.

Gañán, L., et al. “Management of Recurrent Head and Neck Cancer: Variables Related to Salvage Surgery.” European Archives of Oto-Rhino-Laryngology, 2016.

Gooi, Z., et al. “AHNS Series: Do You Know Your Guidelines? Principles of Radiation Therapy for Head and Neck Cancer: A Review of the National Comprehensive Cancer Network Guidelines.” Head & Neck, 2016.

Hoenle, A., et al. “HPV-Specific Treatment Trends in Oropharyngeal Squamous Cell Carcinoma: A Population-Based Analysis With Stage-Stratified Interaction Testing.” European Archives of Oto-Rhino-Laryngology, 2026.

Holsinger, F. C., et al. “Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline.” Journal of Clinical Oncology, 2025.

Koyfman, S. A., et al. “Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.” Journal of Clinical Oncology, 2019.

Leddon, J. L., et al. “Phase 2 Trial of Adjuvant Nivolumab Following Salvage Resection in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck.” Clinical Cancer Research, 2022.

Lim, Y. X., et al. “Clinical, Morphologic and Molecular Heterogeneity of HPV-Associated Oropharyngeal Cancer.” Oncogene, 2023.

Maghami, E., et al. “Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline.” Journal of Clinical Oncology, 2020.

Margalit, D. N., et al. “Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.” Practical Radiation Oncology, 2024.

Mehanna, H., et al. “Prognostic Implications of P16 and HPV Discordance in Oropharyngeal Cancer (HNCIG-EPIC-OPC): A Multicentre, Multinational, Individual Patient Data Analysis.” Lancet Oncology, 2023.

Mody, M. D., et al. “Head and Neck Cancer.” Lancet, 2021.

National Comprehensive Cancer Network. Head and Neck Cancers (Version 2.2026), 2026.

Nichols, A. C., et al. “Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial.” Journal of Clinical Oncology, 2024.

Park, D. A., et al. “Comparative Safety and Effectiveness of Transoral Robotic Surgery Versus Open Surgery for Oropharyngeal Cancer: A Systematic Review and Meta-Analysis.” European Journal of Surgical Oncology, 2020.

Patel, S. N., et al. “Salvage Surgery for Locally Recurrent Oropharyngeal Cancer.” Head & Neck, 2016.

Petrelli, F., et al. “Comparison of Different Treatments for HPV+ Oropharyngeal Carcinoma: A Network Meta-Analysis.” European Archives of Oto-Rhino-Laryngology, 2023.

Quan, D. L., et al. “Surgical Salvage of Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Randomized Controlled Trial.” Cancer, 2023.

Roselló, À., et al. “Transoral Robotic Surgery vs Open Surgery in Head and Neck Cancer. A Systematic Review of the Literature.” Medicina Oral Patología Oral y Cirugía Bucal, 2020.

Ward, M. C., et al. “Salvage of Locoregionally Recurrent Head and Neck Cancer: An NRG Oncology Working Group Review.” Journal of the National Cancer Institute, 2026.

• Background and Rationale:
  • Human papillomavirus (HPV)-associated (p16-positive) oropharyngeal squamous cell carcinoma (OPSCC):
    • Is a biologically distinct, prognostically favorable disease compared with HPV-negative disease
  • Historically, patients received definitive chemoradiation or surgery followed by uniform adjuvant chemoradiation:
    • Producing excellent cancer control but substantial long-term toxicity:
      • Dysphagia, xerostomia, fibrosis, osteoradionecrosis
  • The central question of E3311 was:
    • Whether upfront transoral surgery (TOS), by providing accurate surgical pathology:
      • Could be used to stratify patients by recurrence risk and thereby safely de-intensify adjuvant therapy:
        • Reducing radiation dose (or omitting radiation entirely) in lower-risk patients while reserving full-intensity chemoradiation for high-risk pathology
    • A secondary but pivotal aim was:
      • To demonstrate that a multi-institutional cooperative-group transoral surgical trial, with formal surgeon credentialing, was feasible (Ferris et al., Journal of Clinical Oncology, 2022)
  • Study Design:
    • Phase:
      • II, prospective, multi-institutional (ECOG-ACRIN Cancer Research Group):
        • With randomization embedded in the intermediate-risk group
    • Population:
      • Resectable, p16+ OPSCC
      • AJCC 7th edition T1 to T2
      • Clinical stage III / IVa
      • No matted nodes
      • Candidates for transoral resection
    • Surgical quality control:
      • Participating surgeons underwent formal credentialing:
        • To ensure consistent transoral oncologic technique
    • Intervention:
      • All patients underwent primary transoral surgery (robotic or laser) plus neck dissection:
        • Followed by assignment to one of four pathology-based arms (Ferris et al., Journal of Clinical Oncology, 2022)
• Risk Stratification and Treatment Arms

• Key operational definitions used in E3311 (important when comparing with other trials):
  • Positive margin = tumor-on-ink
  • Close margin = < 3 mm (contrast with ORATOR / MC1675, which used > 5 mm as clear)
• Patients in the intermediate-risk group were randomized between 50 Gy (Arm B) and 60 Gy (Arm C)
  • The trial was not powered for a direct head-to-head comparison of B vs. C:
    • Instead each arm was independently compared against a historical efficacy benchmark (Ferris et al., Journal of Clinical Oncology, 2022)
• Primary Results (Ferris et al., Journal of Clinical Oncology, 2022) – see Table 1
  • Interpretation:
    • Among 359 evaluable patients (median follow-up 35.2 months):
      • Approximately 70% of patients were de-intensified relative to standard adjuvant chemoradiation
      • Two-year progression-free survival (PFS) was excellent across all arms, and both intermediate-risk arms cleared the prespecified efficacy boundary (lower limit of the 90% CI > 85%)
        • Both intermediate-dose arms exceeded the historical benchmark:
          • Supporting 50 Gy as an adequate adjuvant dose for intermediate-risk disease
        • Functional and quality-of-life measures (FACT-H&N, MD Anderson Dysphagia Inventory):
          • Favored the reduced-dose approach, reinforcing the clinical value of de-escalation (Ferris et al., Journal of Clinical Oncology, 2022)
• Long-Term Follow-Up (Burtness et al., Journal of Clinical Oncology, 2025): Table 2
  • Mature data at 54 months confirmed durable efficacy across the cohort:
    • Overall 54-month PFS 90.6% and OS 95.3%
  • Key long-term observations (Burtness et al., Journal of Clinical Oncology, 2025):
    • Outcomes did not differ by primary subsite or smoking history
    • Among observed (Arm A) patients:
      • All 4 recurrences occurred in N1 patients:
        • Signaling that patients with N1 disease remain at some risk for late recurrence when radiation is omitted, and warrant careful surveillance or individualized decision-making
• Guideline Integration:
  • NCCN Head and Neck Cancers Guidelines:
    • E3311 is cited to support de-escalation of adjuvant radiotherapy to 50 Gy (category 2B) in p16+ OPSCC with ≤ 4 positive ipsilateral nodes (largest ≤ 6 cm), T1 to T2 resected to negative or close (< 3 mm) margins, and ≤ 1 mm ENE — mirroring the E3311 intermediate-risk criteria (National Comprehensive Cancer Network, Head and Neck Cancers, 2026)
  • ASCO Transoral Robotic Surgery (TORS) Guideline (2025):
    • E3311 is the largest prospective trial underpinning pathology-driven, risk-adapted adjuvant therapy after TORS
    • It supports adding concurrent cisplatin for positive margins (tumor-on-ink) or ENE, and informs the risk-based selection of radiation dose (Holsinger et al., Journal of Clinical Oncology, 2025)
• Contextual Comparisons and Caveats:
  • Definitional heterogeneity:
    • E3311’s 3 mm close-margin and tumor-on-ink positive-margin thresholds differ from other de-escalation trials (e.g., ORATOR, MC1675), which affects cross-trial comparison of toxicity and control
  • Postoperative vs. definitive setting:
    • E3311’s favorable de-escalation outcomes contrast with NRG-HN005, where dose reduction to 60 Gy in the definitive chemoradiation setting did not meet non-inferiority:
      • This suggests the smaller tumor volume of the postoperative setting may better tolerate dose reduction (Ma et al., Lancet Oncology, 2025)
  • Trial scope:
    • Phase II design and lack of power for direct B-vs-C comparison mean 50 Gy and 60 Gy were each validated against a benchmark rather than against each other
• Distinguishing E3311 from E1308:
  • If the trial of interest was E1308 (a separate ECOG-ACRIN study):
    • The trial tested induction chemotherapy (cisplatin / paclitaxel / cetuximab) followed by reduced-dose IMRT (54 Gy) with cetuximab in HPV-associated resectable OPSCC:
      • Among primary-site complete responders, 2-year PFS and OS were 80% and 94%, with improved swallowing at the lower dose (Marur et al., Journal of Clinical Oncology, 2017)
      • E1308 uses an induction / organ-preservation strategy, distinct from E3311’s surgery-first, pathology-guided strategy
• Key Takeaways:
  • E3311 established that upfront transoral surgery can guide risk-based de-intensification of adjuvant therapy in HPV+ OPSCC within a credentialed, multi-institutional framework
  • ~ 70% of patients were safely de-intensified, with excellent 2-year and durable 54-month PFS / OS across all arms
  • 50 Gy is adequate for intermediate-risk pathology:
    • Clear margins, 2 to 4 nodes or ENE ≤ 1 mm)
  • Observation alone yielded outstanding control in low-risk disease:
    • But N1 patients accounted for the Arm A recurrences and merit vigilance
  • E3311 now anchors NCCN (50 Gy, category 2B) and ASCO TORS guidance on adjuvant management after transoral surgery

• Cisplatin is the cornerstone systemic agent in locally advanced head and neck squamous cell carcinoma (HNSCC)
• Concurrent Chemoradiation (Definitive Setting):
  • Standard of care for locally advanced, unresectable HNSCC (or when organ preservation is desired, e.g., larynx, oropharynx).
• High-dose cisplatin: 100 mg/m² IV every 3 weeks × 3 cycles concurrent with radiation therapy.
• Alternative (for toxicity or frailty): weekly low-dose cisplatin (30–40 mg/m²).
• Evidence: Landmark trials (EORTC, RTOG) showed improved overall survival and locoregional control when cisplatin was added to radiation versus radiation alone.

2. Adjuvant (Postoperative) Chemoradiation

• Indicated for high-risk features after surgery:
  • Positive margins
  • Extracapsular nodal extension
• High-dose cisplatin concurrent with adjuvant radiation reduces recurrence and improves survival (EORTC 22931, RTOG 9501).

3. Palliative / Metastatic Disease

• Cisplatin combined with 5-FU or taxanes, historically standard in recurrent/metastatic disease.
• More recently, cisplatin used in combination with immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) in first-line regimens (KEYNOTE-048).

Key Points for Clinical Use

• Highly emetogenic → requires aggressive antiemetic prophylaxis (NK1 antagonist + 5HT3 antagonist + dexamethasone).
• Toxicities: nephrotoxicity, ototoxicity, neurotoxicity, myelosuppression.
• Alternative for cisplatin-ineligible patients: carboplatin ± 5-FU, or immunotherapy-based regimens.

✅ Summary: Cisplatin exerts its anti-cancer effects by forming DNA crosslinks that trigger apoptosis. In head and neck cancer, it is the backbone of definitive chemoradiation, adjuvant chemoradiation for high-risk patients, and palliative regimens. High-dose cisplatin remains the gold standard for fit patients, with weekly dosing or alternative agents reserved for those with comorbidities.

Would you like me to also prepare a slide-ready summary table comparing cisplatin 100 mg/m² q3w vs 40 mg/m² weekly in head and neck chemoradiation (efficacy, toxicity, compliance)? That’s a common journal club/board question.

You said:

mechanism of acton

ChatGPT said:

Here’s a clear explanation of the mechanism of action of cisplatin (the essence, without the broader oncology indications):

Mechanism of Action of Cisplatin

1. Cell Entry
   • Cisplatin enters tumor cells by passive diffusion and through membrane transporters (notably copper transporters such as CTR1).
2. Activation (Aquation)
   • In the bloodstream, cisplatin is relatively stable because of high chloride concentrations.
   • Once inside the cell (where chloride concentration is lower), cisplatin undergoes aquation: its chloride ligands are replaced by water molecules, creating a highly reactive, positively charged complex.
3. DNA Interaction
   • The activated cisplatin binds strongly to guanine and adenine bases in DNA.
   • It forms:
     • Intrastrand crosslinks (most common: between adjacent guanines or guanine–adenine)
     • Interstrand crosslinks
     • DNA–protein crosslinks
4. Cellular Consequences
   • These DNA adducts distort the double helix, blocking replication and transcription.
   • DNA damage response pathways are activated (p53-dependent and independent).
   • When repair is unsuccessful, this leads to cell-cycle arrest and apoptosis (programmed cell death).
5. Other Effects
   • Cisplatin can also interact with RNA and proteins, contributing to its cytotoxicity.
   • Oxidative stress and mitochondrial dysfunction also play a role in cell death.

✅ In short: Cisplatin kills cancer cells by forming DNA crosslinks that prevent proper replication and transcription, ultimately triggering apoptosis.

Cisplatin is the cornerstone systemic agent in locally advanced head and neck squamous cell carcinoma (HNSCC).

1. Concurrent Chemoradiation (Definitive Setting)

• Standard of care for locally advanced, unresectable HNSCC (or when organ preservation is desired, e.g., larynx, oropharynx).
• High-dose cisplatin: 100 mg/m² IV every 3 weeks × 3 cycles concurrent with radiation therapy.
• Alternative (for toxicity or frailty): weekly low-dose cisplatin (30–40 mg/m²).
• Evidence: Landmark trials (EORTC, RTOG) showed improved overall survival and locoregional control when cisplatin was added to radiation versus radiation alone.

2. Adjuvant (Postoperative) Chemoradiation

• Indicated for high-risk features after surgery:
  • Positive margins
  • Extracapsular nodal extension
• High-dose cisplatin concurrent with adjuvant radiation reduces recurrence and improves survival (EORTC 22931, RTOG 9501).

3. Palliative / Metastatic Disease

• Cisplatin combined with 5-FU or taxanes, historically standard in recurrent/metastatic disease.
• More recently, cisplatin used in combination with immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) in first-line regimens (KEYNOTE-048).

Key Points for Clinical Use

• Highly emetogenic → requires aggressive antiemetic prophylaxis (NK1 antagonist + 5HT3 antagonist + dexamethasone).
• Toxicities: nephrotoxicity, ototoxicity, neurotoxicity, myelosuppression.
• Alternative for cisplatin-ineligible patients: carboplatin ± 5-FU, or immunotherapy-based regimens.

✅ Summary: Cisplatin exerts its anti-cancer effects by forming DNA crosslinks that trigger apoptosis. In head and neck cancer, it is the backbone of definitive chemoradiation, adjuvant chemoradiation for high-risk patients, and palliative regimens. High-dose cisplatin remains the gold standard for fit patients, with weekly dosing or alternative agents reserved for those with comorbidities.

Would you like me to also prepare a slide-ready summary table comparing cisplatin 100 mg/m² q3w vs 40 mg/m² weekly in head and neck chemoradiation (efficacy, toxicity, compliance)? That’s a common journal club/board question.

You said:

mechanism of acton

ChatGPT said:

Here’s a clear explanation of the mechanism of action of cisplatin (the essence, without the broader oncology indications):

Mechanism of Action of Cisplatin

1. Cell Entry
   • Cisplatin enters tumor cells by passive diffusion and through membrane transporters (notably copper transporters such as CTR1).
2. Activation (Aquation)
   • In the bloodstream, cisplatin is relatively stable because of high chloride concentrations.
   • Once inside the cell (where chloride concentration is lower), cisplatin undergoes aquation: its chloride ligands are replaced by water molecules, creating a highly reactive, positively charged complex.
3. DNA Interaction
   • The activated cisplatin binds strongly to guanine and adenine bases in DNA.
   • It forms:
     • Intrastrand crosslinks (most common: between adjacent guanines or guanine–adenine)
     • Interstrand crosslinks
     • DNA–protein crosslinks
4. Cellular Consequences
   • These DNA adducts distort the double helix, blocking replication and transcription.
   • DNA damage response pathways are activated (p53-dependent and independent).
   • When repair is unsuccessful, this leads to cell-cycle arrest and apoptosis (programmed cell death).
5. Other Effects
   • Cisplatin can also interact with RNA and proteins, contributing to its cytotoxicity.
   • Oxidative stress and mitochondrial dysfunction also play a role in cell death.

✅ In short: Cisplatin kills cancer cells by forming DNA crosslinks that prevent proper replication and transcription, ultimately triggering apoptosis.